Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation.

ABSTRACT:

Objective

We studied evolving antithrombotic therapy patterns in patients with newly diagnosed non-valvular atrial fibrillation (AF) and ≥1 additional stroke risk factor between 2010 and 2015.

Methods

39 670 patients were prospectively enrolled in four sequential cohorts in the Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF): cohort C1 (2010-2011), n=5500; C2 (2011-2013), n=11 662; C3 (2013-2014), n=11 462; C4 (2014-2015), n=11 046. Baseline characteristics and antithrombotic therapy initiated at diagnosis were analysed by cohort.

Results

Baseline characteristics were similar across cohorts. Median CHA₂DS₂-VASc (cardiac failure, hypertension, age ≥75 (doubled), diabetes, stroke (doubled)-vascular disease, age 65-74 an

SUBMITTER: Camm AJ 

PROVIDER: S-EPMC5293840 | biostudies-literature | 2017 Feb

REPOSITORIES: biostudies-literature